Ordinary and Extraordinary General Meeting of May 12, 2022
April 21 2022 - 3:30PM
Montrouge, France, April 21, 2022Ordinary
and Extraordinary General Meeting of May
12, 2022
Procedures for Obtaining Preparatory
Documents for the General Meeting
DBV Technologies (Euronext: DBV – ISIN:
FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage
biopharmaceutical company, announced that it will hold its Ordinary
and Extraordinary General Meeting on May 12, 2022, at 8:30 a.m.
CEST at the Company’s headquarters located at 177-181 Avenue Pierre
Brossolette – 92120 Montrouge, France.
The preliminary notice (l'avis préalable)
containing the detailed agenda, draft resolutions as well as
instructions to participate and vote for this meeting was published
in the French “Bulletin des Annonces Légales Obligatoires (BALO)”
dated April 6 and April 13, 2022 (No. 2200757 and No. 2200917).
To ensure that shareholders are properly informed,
an additional resolution (the 21st resolution) has been added to
the agenda of the Combined General Meeting as detailed in the US
preliminary proxy statement filed with the SEC on April 14, 2022,
and in the notice of meeting (l'avis de convocation) that will be
published in the BALO and in the Legal Gazette on April 25,
2022.
The preparatory documents for the General Meeting
listed in article R. 225-73-1 of the French Commercial Code are
posted on the Investors & Media section of the Company’s
website located at:
https://www.dbv-technologies.com/investor-relations/financial--information/annual-reports/
The documents for the General Meeting will also be
made available to shareholders as of the date of the issuance of
the convening notice. Thus, in accordance with applicable law and
regulations:
- Any shareholder holding registered
shares may, until the fifth day prior to the General Meeting,
request that the Company send them the documents required under
articles L. 225-115 and R. 225-83 of the French Commercial Code,
electronically at their express request. For shareholders holding
bearer shares, the exercise of this right is subject to the
submission of a certificate of participation in the bearer share
accounts held by the authorized financial intermediary.
- Any shareholder may consult the
documents and information referred to in articles L. 225-115 and R.
225-83 of the French Commercial Code, which are available at the
Company’s headquarters.
Webcast of the General MeetingOn
May 12, 2022, starting at 8:30 a.m. CEST, the General Meeting will
be webcast live on the Company's website
https://www.dbv-technologies.com/fr/ in the “Events and
Presentations” section.
Shareholders will also be able to access a replay
of the Meeting on the Company's website for two years following the
General Meeting.
About DBV
Technologies DBV Technologies is developing
Viaskin™, an investigational proprietary technology platform with
broad potential applications in immunotherapy. Viaskin is based on
epicutaneous immunotherapy, or EPIT™, DBV’s method of delivering
biologically active compounds to the immune system through intact
skin. With this new class of non-invasive product candidates, the
Company is dedicated to safely transforming the care of food
allergic patients. DBV’s food allergies programs include ongoing
clinical trials of Viaskin Peanut. DBV Technologies has global
headquarters in Montrouge, France, and North American operations in
Basking Ridge, NJ. The Company’s ordinary shares are traded on
segment B of Euronext Paris (Ticker: DBV, ISIN code: FR0010417345),
part of the SBF120 index, and the Company’s ADSs (each representing
one-half of one ordinary share) are traded on the Nasdaq Global
Select Market (Ticker: DBVT).
Investor
Contact Anne PollakDBV Technologies+1
857-529-2363anne.pollak@dbv-technologies.com
Media
ContactAngela MarcucciDBV
Technologies+1 646-842-2393angela.marcucci@dbv-technologies.com
DBV Technologies (EU:DBV)
Historical Stock Chart
From May 2024 to Jun 2024
DBV Technologies (EU:DBV)
Historical Stock Chart
From Jun 2023 to Jun 2024